Cogent Biosciences Inc. reported cash, cash equivalents, and marketable securities of USD 900.8 million as of December 31, 2025, citing non-recurring fourth quarter cash usage primarily driven by the repayment of USD 54.8 million in long-term debt and approximately USD 38.5 million in one-time, performance-based equity compensation. The company stated that its strong financial position is expected to fund operations into 2028. During the period, Cogent submitted a SUMMIT NDA for bezuclastinib in patients with NonAdvSM in December 2025 and confirmed that the APEX NDA submission for bezuclastinib in patients with AdvSM remains on track for the first half of 2026. The PEAK NDA for bezuclastinib in patients with 2L GIST was initiated under Real-Time Oncology Review and Breakthrough Therapy Designation, with completion targeted for April 2026. Six abstracts from the SUMMIT trial in NonAdvSM were accepted for presentation at the 2026 AAAAI annual meeting. Additionally, on February 11, 2026, Cogent’s Board approved inducement equity awards for twelve new employees, granting options to purchase 59,300 shares and 47,000 restricted stock units.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cogent Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602170800PRIMZONEFULLFEED9655544) on February 17, 2026, and is solely responsible for the information contained therein.